BNT162b2 vaccine effectiveness 92 percent for teens ages 12 to 17
FDA may allow Pfizer boosters for 12- to 15-year-olds by Monday
30 December 2021HIV patients ‘cured’ by their own unique biology may harbor secrets to end the global scourge
31 December 2021BNT162b2 vaccine effectiveness 92 percent for teens ages 12 to 17
(HealthDay)—For adolescents ages 12 to 17 years, the effectiveness of full vaccination with two doses of the Pfizer-BioNTech vaccine is 92 percent against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to research published in the Dec. 31 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
